Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo


Unsupported browser: Your browser does not meet modern web standards. See how it scores »

{ action.text }

Even though antibiotics have been available for more than 50 years, tuberculosis remains a major killer: In 2009, 1.7 million people, largely from poor countries, died from the disease, according to a recent World Health Organization (WHO) report. Tawanda Gumbo, a physician and researcher at the University of Texas Southwestern Medical School, aims to change that by better tailoring courses of antibiotics to individual patients.

Gumbo has spent the last 10 years studying the effects of common tuberculosis drugs in test tubes and in animals in an effort to find the most effective doses. He has also employed mathematical simulations—a technique borrowed from engineering—to figure out how different variables, such as weight, gender, and genetic variations in both the microbe and the patient, change the optimal dose. “If you give the same dose to 100 children, you get 100 different pictures,” says Gumbo. “Given all of this variability, how should I dose different children?”

Gumbo is now ready to test his theories with the launch of a clinical trial of TB-infected children in South Africa. He hopes that tailoring doses to the individual will help shorten treatment regimens, which typically last six months, and slow the development of drug-resistant strains of the bacterium. The emergence of multidrug resistant cases—a form of the disease that is difficult and costly to treat because it does not respond to first-line drugs—is at its highest rate ever, according to WHO.

In the clinical trial, Gumbo and his collaborators will examine genetic variability of the microbe infecting a particular patient by assessing its genome as well as how susceptible it is to particular drug. Patients will get genotyping tests to determine whether they have specific mutations that influence how well they metabolize specific drugs. 

Public health agencies largely blame the development of drug resistance to TB on patients not finishing their antibiotic regimens.  But Gumbo thinks chronic underdosing could be a major contributor as well. “If you go to places with good treatment programs, where they administer and monitor drugs [according to guidelines], you still see high failure rates,” says Gumbo.  “If they are doing everything they are supposed to do, why is there still drug resistance?”

According to his research, “the doses needed have almost always been much higher than what we’ve been giving currently,” says Gumbo. “And we know from what we have done in the lab that if you achieve these higher concentrations, you can probably treat for shorter periods of time.”

The idea is still somewhat controversial, but “he is slowly winning converts in the TB community about the importance of proper dose selection,” says Paul Ambrose, director of the Institute for Clinical Pharmacodynamics at the Ordway Research Institute, and a former collaborator of Gumbo’s.

1 comment. Share your thoughts »

Credit: CDC/ Dr. Ray Butler

Tagged: Biomedicine, antibiotics, tuberculosis, drug resistance, microbe

Reprints and Permissions | Send feedback to the editor

From the Archives


Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me